CLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CLX is not a good buy right now for a beginner long-term investor with $50,000-$100,000 ready to deploy. The stock has some value-support from its dividend and mild price stabilization, but the overall picture is still too weak: analysts are broadly cutting targets and leaning bearish, technical trend remains longer-term bearish, and recent news points to margin pressure, slower growth, and securities investigations. For an impatient investor, this is not a strong immediate buy.
CLX is trading at 91.47 after a small gain from the prior close, but the regular session was still negative overall. The MACD histogram is positive and expanding, which suggests short-term momentum is improving. However, RSI at 48.1 is neutral, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5, indicating the broader trend is still weak. Price is sitting near pivot support at 89.22, with nearby resistance at 92.57 and 94.64. The short-term setup is mixed, but the longer-term trend remains bearish rather than confirming a strong entry.
["Dividend yield is elevated, which may attract income-focused long-term holders.", "MACD histogram is positive and expanding, showing some short-term momentum improvement.", "Analyst target cuts have brought expectations lower, which can sometimes set up stabilization if fundamentals stop deteriorating.", "No significant insider selling and no notable hedge fund accumulation trends were reported."]
["Multiple analysts cut price targets after earnings and several maintain Sell/Underweight/Underperform views.", "The company issued weaker FY26 guidance and cited cost pressures, soft consumer trends, and ERP transition impacts.", "News reports mention securities investigations related to misleading statements and declining performance.", "Bearish moving average structure shows the long-term trend is still weak.", "Recent stock trend data suggests downside over the next week and month.", "Dividend sustainability concerns were raised due to insufficient free cash flow.", "No AI Stock Picker or SwingMax buy signal is active today."]
No usable financial snapshot was available, so the latest quarter cannot be assessed directly from the provided financial data. Based on the analyst commentary tied to the Q3 report, Clorox posted a slight EPS beat in Q3, but guidance for FY26 was cut and the outlook weakened due to cost inflation, demand softness, and margin pressure. The latest reported season was Q3, and the key takeaway is that earnings quality and forward growth visibility look pressured rather than improving.
Analyst sentiment has turned noticeably more cautious. In early May 2026, Goldman Sachs, JPMorgan, Barclays, Evercore ISI, and others lowered price targets, with several maintaining bearish ratings such as Sell, Underweight, and Underperform. A few firms remain Neutral/Hold, and Jefferies still has a Buy, but the overall direction is clearly downward. Wall Street's pro view is that the stock may now be cheaper and supported by its dividend, while the con view is that sales weakness, cost inflation, and reduced guidance outweigh valuation appeal. The balance of analyst opinion is negative.
